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solves type 2 diabetes. However, this finding has been contradicted by several experimental
and human trials and therefore needs to be clarified.
Methods: Otsuka LongeEvans Tokushima Fatty (OLETF) rats randomly underwent a sham oper-
ation or DJB. Thereafter, we measured daily body weight, serum levels of glucose and gut hor-
mones such as glucagon-like peptide-1, insulin, and leptin.
Results: There was no significant difference in weight loss between rats in the DJB and sham-
operated groups. There were also no differences in the area under the curve of glucose toler-
ance between the DJB and sham-operated groups (32466  2261 mg/dL$min vs.
26319  427 mg/dL$min; p Z 0.35). Duodenojejunal bypass did not affect plasma
concentrations of various gut hormones such as glucagon-like peptide-1, insulin, and leptin.
Conclusions: We have shown that DJB alone does not improve glucose tolerance in obese, dia-
betic OLETF rats. Therefore, it may be that DJB alone is insufficient for diabetic control inave no financial conflicts of interest to disclose.
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reserved.1. Introduction
The worldwide prevalence of diabetes in adults was
approximately 6.4% in 2010 and is estimated to increase to
7.7% by 2030, which represents approximately 439 million
diabetic patients.1 The increase in the prevalence of type
2 diabetes worldwide parallels the recent rise in obesity.
Some authors have thus proposed the terminology “dia-
besity” because the link between diabetes and obesity is
so strong that there are many common factors in treat-
ment strategies.1 The efforts of surgeons to treat obesity
through surgical methods led to bariatric surgery in the
1950s.2 Recent meta-analyses of 16 studies that involved
6131 patients with a mean follow-up of 17.3 months have
clearly demonstrated the superiority of bariatric surgery
over conventional medical therapy in the treatment of
obesity and type 2 diabetes.3 This meta-analysis also
revealed that the overall remission rate of type 2 diabetes
after bariatric surgery is approximately four times higher
than the rate after medical therapy (63.5% vs. 15.6%,
p < 0.001).
Bariatric surgery generally involves restrictive and
bypass components. Duodenojejunal bypass (DJB) repre-
sents a bypass component of bariatric surgery. It refers to
the exclusion of the duodenum and the proximal jejunum
from the passage of food. Rubino and Marescaux4 first
investigated the effect of DJB on controlling glucose levels
in the Goto-Kakizaki rat, which is a spontaneous nonobese
model of type 2 diabetes mellitus. In the report, the re-
searchers observed that glucose tolerance significantly
improved after DJB, despite no significant weight reduc-
tion. Rubino et al.4 provided two remarkable suppositions
for the antidiabetic effects of DJB. First, the foregut hy-
pothesis states that the exclusion of the foregut from the
transit of nutrients may prevent the secretion of putative
secretions that aggravate glucose control in diabetes.5,6
Second, the hindgut hypothesis states that the expedited
delivery of nutrients prompts secretion of glucagon-like
peptide-1 (GLP-1) and/or other distal gut peptides from
the distal intestinal cells, which improves glucose
metabolism.7e9
However, subsequent studies did not consistently sup-
port the glucose-lowering effect of DJB. In several experi-
mental animal models, it has been observed that the
glucose-lowering effect of DJB was temporary and did not
last for a lengthy period of time.10,11 The DJB surgery was
also attempted clinically in patients with type 2 diabetes
and a body mass index less than 35 kg/m2.12 There was
improvement in glycemic control in these patients, but it
was a modest improvement, and no patient experienced a
complete remission of type 2 diabetes. The OtsukaLee SK, et al., Long-term effec
of Surgery (2016), http://dx.doi.LongeEvans Tokushima Fatty (OLETF) strain of rats de-
velops hyperglycemia gradually after birth along with
obesity,13 which closely resembles the development of type
2 diabetes with obesity in humans. The expression of a
functional cholecystokinin-1 receptor is inhibited,14e16
therefore, these rats fail to feel satiety and consume
double the amount of a spontaneous meal size, compared
to normal rats. Therefore, the OLETF rat model could be a
reasonable representative of patients with type 2 diabetes
and obesity, who account for a substantial proportion of
patients undergoing bariatric surgery. Thus, the goals of
this study were to determine the glucose-controlling effect
of DJB in the OLETF rat model and to investigate DJB-
related changes in gut hormones associated with glucose
metabolism.
2. Materials and Methods
2.1. Animals
The animal protocol was approved by the Institutional
Animal Care and Use Committee in School of Medicine at
the Catholic University of Korea (Seoul, Korea). Male 5-
week-old OLETF rats were provided by the Tokushima
Research Institute, Otsuka Pharmaceutical (Tokushima,
Japan). Before the beginning of the study, the rats were
acclimated to their environment for 1 week. They were
allowed free access to a gamma-ray-sterilized diet (Pico
5053; LabDiet, St. Luis, MO) and autoclaved tap water in a
specific pathogen-free environment. They were main-
tained in a clean room at 22.5C  1C and relative hu-
midity of 50%  10% under an automatic 12-hour light/
dark cycle. They were housed until they were aged
26 weeks of life to allow the full development of the
diabetic condition.
2.2. Surgical procedures
After fasting for 12 h, the rats were anesthetized with
inhalation of 2% isofluorane and oxygen. Before surgery, the
rats were administered an intramuscular administration of
antibiotics (cefazolin, 30 mg/kg). The peritoneum was
entered through a midline incision of approximately
5e6 cm. In the DJB group, a DJB was performed as previ-
ously described4,17 (Fig. 1). In brief, the duodenum was
divided just distal to the pylorus, and the jejunum was
divided 8 cm distal to the ligament of Treitz. The distal
duodenal stump was then sewn closed. End-to-end duode-
nojejunostomy was created by anastomosing the proximal
segment of the divided duodenum to the distal segment ofts of duodenojejunal bypass on diabetes in Otsuka LongeEvans
org/10.1016/j.asjsur.2015.11.001
Figure 1 Anatomy of the duodenojejunal bypass (DJB). The
duodenum is divided immediately distal to the pylorus, and the
duodenal end is closed. The jejunum is transected 8 cm distal
to the Treitz ligament, and the distal end of the jejunum is
anastomosed to the proximal end of the duodenum. The je-
junal proximal end is anastomosed to the jejunum, 12 cm distal
to the duodenojejunostomy.
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+ MODELdivided jejunum using absorbable suture material (PDS II 6-
0; Ethicon, Somerville, NJ). A partial jejunal enterotomy
was created 12 cm distal to the duodenojejunostomy, and
then an end-to-side jejunojejunostomy was created with
the same suture material by anastomosing the proximalFigure 2 The operative illustration of the duodenojejunal bypas
schematic drawing depicting the DJB.
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(Fig. 2). After establishing all anastomoses, they were
gently squeezed to check for leakage. During the proce-
dure, the abdomen was intermittently irrigated with warm
sterile saline to prevent dehydration. The abdominal wall
was closed in two layers with absorbable suture (Vicryl 3-0;
Ethicon, Somerville, NJ).
For the sham-operated group, the rats underwent lapa-
rotomy using the aforementioned protocol. After accessing
the abdominal cavity, the gastrointestinal tract was inten-
tionally manipulated and irrigated. The jejunum and ileum
were traced from the beginning to the end. The sham
operation lasted approximately the same amount of time as
the DJB procedure.
After surgery, the rat was placed in its cage under a heat
lamp to prevent hypothermia during recovery. The rats
were administered a single intramuscular administration of
parenteral analgesics (ketorolac, 5 mL/kg), and subcu-
taneous injections of normal saline (2 mL) three times a day
for preventing dehydration. The weight of the animals was
measured and recorded daily. For the first 24 hours post-
surgery, the rats had free access to water. Twenty-four
hours postsurgery, the rats received a liquid diet (5%
glucose) until postoperative Day 3, at which point an un-
limited normal diet was provided for the remainder of the
study.
2.3. Fasting blood sugar measurement and oral
glucose tolerance test
After fasting for 12 hours, an oral glucose tolerance test
(OGTT) was performed 1 week before surgery and 4 weeks
after surgery. D-Glucose (2 g/kg) was administered by oral
gavage. Serum glucose levels were measured before gavage
(at fasting) and at 0 minutes, 30 minutes, 60 minutes, and
120 minutes after gavage using a hand-held glucometer
(OneTouch/LifeScan; Johnson & Johnson, Milpitas, CA) vias (DJB). (A) The operative picture of DJB establishment. (B) A
ts of duodenojejunal bypass on diabetes in Otsuka LongeEvans
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Figure 3 Effects of duodenojejunal bypass (DJB) or sham
operation (Sham Op.) on the body weight of Otsuka Long-
eEvans Tokushima Fatty (OLETF) rats. (A) Weight changes over
time for the DJB and sham groups on a daily basis. (B) Weight
changes over time for the DJB and sham groups on a weekly
basis. (C) The percentage of total body weight loss over time
for the DJB and sham groups. Statistical data are presented as
the mean the standard error. * p < 0.05.
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EDTA-coated tubes, centrifuged, and stored at 20C for
subsequent analysis.
2.4. Hormonal assays
Blood samples were obtained from the tail vein after
12 hours of fasting. After collection, blood samples were
immediately placed in an icebox and centrifuged. The
plasma fraction was separated by centrifugation at 4C and
preserved at 80C until the assays were performed.
Enzyme-linked immunosorbent assay (ELISA) or radioim-
munoassay (RIA) was used to determine the serum levels of
GLP-1 (GLP-1 (7-36)-Amide Human, Rat, Mouse EIA Kit;
Phoenix Pharmaceuticals, Belmont, CA) and insulin (Insulin
ELISA Kit; DRG International, Inc. Mountainside, NJ) in
accordance with the manufacturer’s instructions.
2.5. Statistical analysis
All data are presented as the mean  the standard error. A
two-way analysis of variance, followed by the Bonferroni
post hoc test, was used for comparisons between the two
groups (i.e., sham operation group and DJB group) over
time. Comparisons between groups were performed by the
Wilcoxon rank sum test, and comparisons in the group
(paired data such as pre- and postoperative data) were
performed by Wilcoxon singled rank test. A value of
p < 0.05 was considered statistically significant. Statistical
analyses were performed using the software SPSS 18.0 (SPSS
Inc., Chicago, IL). The OGTT values of the area under the
curve (AUC) were calculated using the trapezoidal inte-
gration method.
3. Results
3.1. Effects of DJB on the weight of the OLETF rats
Our study included six OLETF rats and seven OLETF rats in
the DJB and sham groups, respectively. All rats underwent
surgery and survived more than 30 days thereafter. The
mean preoperative age and body weight were
28.7  1.1 weeks and 540.5  15.2 g, respectively, in the
DJB group, and 29.2  1.2 weeks and 563.7  8.6 g,
respectively, in the sham group. There was no statistical
difference in age and body weight between the two groups.
The operation times were 43.6  16.3 minutes and
38.3  15.6 minutes in the DJB and sham groups, respec-
tively (p Z 0.073).
In both groups, the rats’ body weight decreased imme-
diately after surgery. The most prominent decreases in
body weight were observed on postoperative days 2 and 3 in
the DJB and sham groups, respectively. The rats’ body
weight thereafter gradually increased in both groups. The
DJB group had lower body weights at all time points,
compared to the sham group, but without a statistical sig-
nificance (Fig. 3A). We then calculated the percentage of
total body weight loss in both groups (Fig. 3B). The value
was lower in the DJB group than in the sham group until
13 days postsurgery and the difference between groupsPlease cite this article in press as: Lee SK, et al., Long-term effec
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time points, the difference was statistically significant on
postsurgery day 3 (34.4%  3.8% vs. 13.5%  2.8% in the
DJB and sham groups, respectively; p Z 0.046). Thets of duodenojejunal bypass on diabetes in Otsuka LongeEvans
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Figure 4 The effect of duodenojejunal bypass operation
(DJB Op.) or sham operation (Sham Op.) on plasma glucose
concentrations during the oral glucose tolerance test (OGTT).
(A) Blood glucose concentrations during the OGTT in the sham
group. (B) Blood glucose concentrations during the OGTT in the
DJB group. (C) Comparison of the AUC calculations between
the sham and DJB groups 4 weeks after surgery.
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decreased until 30 days postsurgery.
3.2. Effects of DJB on fasting glucose levels and
OGTT
An OGTT was performed 1 week before and 4 weeks after
surgery. Before surgery, the two groups had similar serum
glucose levels at fasting and at 30 minutes, 60 minutes, and
120 minutes after glucose administration (Fig. 4A). Four
weeks after surgery, the DJB group showed slightly higher
fasting glucose level and the OGTT values at 30 minutes and
60 minutes without statistical significance (Fig. 4B). An
analysis of the AUC at 4 weeks after surgery demonstrated
that the OGTT did not differ significantly between the two
groups (pZ 0.35). Taken together, our results suggest that
DJB does not have a glucose-lowering effect in OLETF rats.
3.3. Effects of DJB on plasma levels of gut
hormones
We investigated the changes in gut hormones before and
4 weeks after surgery in each group. There were no sig-
nificant differences in the plasma concentrations of
glucose-dependent insulinotropic polypeptide (GIP), GLP-1,
and leptin before or after surgery in each group (Fig. 5).
Plasma insulin levels significantly decreased after surgery in
both groups (sham group: 27.1  2.6 pg/mL vs.
10.5  1.9 pg/mL, pZ 0.025; DJB group: 31.6  3.8 pg/mL
vs. 10.7  4.2 pg/mL; pZ 0.009), which may be because of
decreased oral intake.
4. Discussion
In this study, we found that DJB alone did not induce a
statistically significant improvement in glucose tolerance
4 weeks after surgery in OLETF rats. The DJB seemed to
induce more weight loss than the sham operation, although
the weight loss was not statistically different. We also
found that DJB did not affect plasma concentrations of
most gut hormones such as GIP, GLP-1, insulin, and leptin.
The DJB surgery has an antidiabetic effect in a variety of
animal models.4,18,19 It is estimated that serum glucose
levels are controlled by the combination effects of incretins
and anti-incretins.17,20e22 Incretins are hormones that
stimulate a decrease in blood glucose levels, and anti-
incretins refer to the putative hormones that would pro-
mote insulin resistance and type 2 diabetes. The former
hormones are primarily released from the hindgut, and the
latter hormones may be released from the foregut. In DJB,
nutrient-rich chyme moves quickly to the distal intestine
and bypass the duodenum and proximal small intestine.
Therefore, the anti-diabetic effect of DJB is possibly
attributed to the higher secretion of incretins from the
hindgut prompted by the rapid transit of nutrients or to the
prevention of secretion of anti-incretins that otherwise
would be released from the foregut.
However, it remains controversial whether DJB exhibits
a significant antidiabetic effect. The antidiabetic effect of
DJB was not reported in previous experiments.10,11 APlease cite this article in press as: Lee SK, et al., Long-term effec
Tokushima Fatty rats, Asian Journal of Surgery (2016), http://dx.doi.oclinical trial showed that DJB resulted in only a modest
effect in controlling glucose levels without the induction of
diabetes remission. In addition, the definite evidence,
including representative hindgut hormones (which stronglyts of duodenojejunal bypass on diabetes in Otsuka LongeEvans
rg/10.1016/j.asjsur.2015.11.001
6 S.K. Lee et al.
+ MODELsupport the hindgut hypothesis) has not been clearly iden-
tified. Glucagon-like peptide-1, which is secreted from the
intestinal L cells, has previously received attention as a
crucial player, based on the observation that a GLP-1 re-
ceptor antagonist effectively prevented the glucose-
lowering effect of DJB.23 To clearly determine the role of
hindgut hormones, several investigators subsequently
established an animal model with ileal transposition (or
interposition), which interposes the distal ileum into theFigure 5 Effects of duodenojejunal bypass (DJB) or sham
operation (Sham Op.) on the plasma levels of gut hormones and
insulin in Otsuka LongeEvans Tokushima Fatty (OLETF) rats.
The plasma levels were measured before surgery and 4 weeks
after surgery in the sham and DJB groups. The measured hor-
mones include (A) glucose-dependent insulinotropic poly-
peptide (GIP), (B) glucagon-like peptide-1 (GLP-1), (C) insulin,
and (D) leptin. Statistical data are presented as the mean the
standard error. * p < 0.05.
Please cite this article in press as: Lee SK, et al., Long-term effec
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expected, ileal transposition increased plasma levels of
GLP-1 by promoting early contact between ingested nutri-
ents and the transposed ileal tissue.25e29 However, there
was only a modest effect of controlling glucose levels.24e29
There have similarly been no reports of detecting putative
anti-incretins released from the foregut.
This study strongly suggests DJB alone is not sufficient to
induce a complete remission of type 2 diabetes, and thus
should be supplemented with other procedures such as
gastric restriction or medications. Roux-en-Y gastric bypass
(RYGB), which induces durable diabetes remission, has both
components of intestinal bypass and gastric restriction. In
five published studies that incorporated 3568 diabetic pa-
tients undergoing RYGB, 82e98% of patients experienced
complete remission of diabetes after this procedure.30e34
As with duodenal bypass, gastric restriction also has a
certain role in regulating the blood glucose level. For
instance, reduced gastric capacity after gastric restriction
produces early satiety and consequently allows patients to
have smaller meals.35,36 In addition, gastric restriction is
associated with a profound loss of appetite.37 The profound
loss of appetite is may result from a decrease in the ghrelin
level because most ghrelin-producing tissues are located in
the gastric fundus.
Ghrelin is an enteric peptide hormone that strongly
stimulates appetite.38e41 Ghrelin also exerts several pro-
diabetogenic effects, including the suppression of insulin
levels and related signaling pathways of glucose meta-
bolism.42,43 Therefore, the antidiabetogenic effect of RYGB
should be attributed to the combination effects of
duodenal bypass and gastric restriction.
Several factors could explain why DJB did not induce a
glucose-lowering effect in our OLETF rat model. First, our
experiment was different from Rubino’s experiment4,17
with respect to time that elapsed before performing the
OGTT. In Rubino’s experiment, the glucose-lowering effect
was evaluated 1 week postoperatively. By contrast, we
measured OGTT 4 weeks after surgery, which is equivalent
to approximately 2 human years considering that 13.7 rat
days is equivalent to 1 human year.44 A study by DiGiorgi
et al.45 determined that approximately 24% of patients
experienced a diabetes recurrence within 3 years after
RYGB. Therefore, in our experiment, there is a possibility of
diabetes recurrence at the time of the OGTT measuring
period, despite the diabetes having been controlled suc-
cessfully in an earlier stage. Second, the antidiabetogenic
effect of DJB could be different among the experimental
diabetes models because the mechanisms inducing diabetes
differ according to the individual models. Rubino et al. used
Goto-Kakizaki rats, which are a highly inbred strain of
glucose-intolerant Wistar rats that spontaneously develop
type 2 diabetes without obesity.46 By contrast, we used
OLETF rats, which develop hyperglycemia gradually after
birth along with obesity,13 which resembles human type 2
diabetes with obesity. Spontaneous meal size is nearly
double in the OLETF rats, compared to the normal rats. In
addition, as they get older, OLETF rats tend to experience a
worsening of their diabetic condition because pancreatic
fibrosis occurs after 20 weeks of age, and atrophic change
occurs at 40 weeks of age.47 Because our rats were 30- to
35-weeks-old at the time of the postoperative OGTT check,ts of duodenojejunal bypass on diabetes in Otsuka LongeEvans
org/10.1016/j.asjsur.2015.11.001
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possibility of diabetes reversal.
As shown in Figure 5, the insulin secretion was reduced
after surgery. We believe this finding is possibly because of
decreased oral intake. This supposition is supported by the
fact that the weight gain in the rats after the operation
were largely limited. The OLETF rats are characterized by
continuous weight gain with aging.48 In addition, the OLETF
rats became hyperglycemic and hyperinsulinemic, based on
increasing oral intake. Therefore, when the oral intake is
reduced in OLETF rats, it is followed by improvement in the
OGTT results and decrease in serum insulin level. Our re-
sults are in line with these observations. By contrast, the
difference in the operative methods (sham or DJB) did not
significantly influence the OGTT results or serum insulin
level. Therefore, we would conclude that DJB is insufficient
to reverse diabetes in OLETF rats.
Our study has several limitations. First, we did not pro-
vide a mixed meal formula, but normal diet. The formula of
meal test affects the degree of glucose metabolism on the
bariatric population. For instance, the higher provision of
protein or lipid is more beneficial in reducing the blood
glucose level, compared to the provision of glucose only,
possibly by increasing incretin secretion more. If we had
used a mixed meal formula instead of a normal diet in this
study, it is possible that the antidiabetic effect by DJB may
have been different. Our study did not include the mea-
surement of postoperative meal sizes. The leading cause of
diabetes in OLEFT rats is the increase in meal size. Otsuka
Long-Evans Tokushima Fatty rats are deficient in the
cholecystokinin (CCK)-1 receptor, which is involved in the
feeding inhibitory mechanism.48 Therefore, OLETF rats,
which fail to inhibit feeding, become hyperphagic and hy-
perglycemic gradually along with obesity. Our study is thus
limited by not providing accurate information about meal
size after DJB.
In conclusion, we have shown that the bypass of the
duodenum and the proximal small intestine did not effec-
tively improve glucose tolerance in obese diabetic OLETF
rats. Hence, this study emphasizes the importance of a
combination therapy such as combined duodenal bypass
and gastric restriction (e.g., RYGB) in inducing glucose
tolerance Therefore, when attempting DJB to achieve
diabetes reversal, it should incorporate a restrictive
component (e.g., sleeve gastrectomy) or a new drug (e.g.,
a GLP-1 analogue) with the DJB.
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